Checkpoint Therapeutics Files 8-K

Checkpoint Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCheckpoint Therapeutics, Inc.
Form Type8-K
Filed DateMay 22, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: 8-K, other-events

Related Tickers: CPTX

TL;DR

CPTX filed an 8-K on 5/22 for an event on 5/19, details TBD.

AI Summary

Checkpoint Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting an event that occurred on May 19, 2025. The filing is categorized under 'Other Events' and does not provide specific details on the nature of the event or any associated financial figures.

Why It Matters

This filing indicates a material event has occurred for Checkpoint Therapeutics, requiring disclosure to investors. The lack of detail necessitates further investigation to understand the implications.

Risk Assessment

Risk Level: medium — The filing is an 8-K, which typically signals a material event, but the lack of specific details in the provided text creates uncertainty about the nature and impact of the event.

Key Players & Entities

  • Checkpoint Therapeutics, Inc. (company) — Registrant
  • May 19, 2025 (date) — Earliest event reported
  • May 22, 2025 (date) — Filing date
  • Delaware (jurisdiction) — State of incorporation
  • 001-38128 (identifier) — Commission File Number
  • 47-2568632 (identifier) — IRS Employer Identification No.
  • 95 Sawyer Road, Suite 110, Waltham, MA 02453 (address) — Principal executive offices
  • 781-652-4500 (phone_number) — Registrant's Telephone Number

FAQ

What specific event is reported in this 8-K filing?

The filing is categorized under 'Other Events' and does not specify the nature of the event that occurred on May 19, 2025.

When was this 8-K filing submitted to the SEC?

The 8-K filing was submitted on May 22, 2025.

What is the exact name of the company filing this report?

The exact name of the company is Checkpoint Therapeutics, Inc.

In which state was Checkpoint Therapeutics, Inc. incorporated?

Checkpoint Therapeutics, Inc. was incorporated in Delaware.

What is the principal executive office address for Checkpoint Therapeutics, Inc.?

The principal executive office address is 95 Sawyer Road, Suite 110, Waltham, MA 02453.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 22, 2025 regarding Checkpoint Therapeutics, Inc..

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.